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ABSTRACT
We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation
in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete
remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429
patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were
performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant
Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95%
confidence interval [CI], 33%-55%). The probability at 3 years of progression-free survival was 31% (95% CI,
27%-36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free
survival of 38% (95% CI, 30%-46%) compared with 28% (95% CI, 22%-33%) for those who were not in
remission at the time of transplantation (P < .001). In multivariate analysis, chemotherapy resistance, increased
lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age >40 years, and use
of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of
survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with
diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive
disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate
recovery for recipients of bone marrow grafts may increase the risk of disease progression or death.
© 2004 American Society for Blood and Marrow Transplantation
KEY WORDS
Non-Hodgkin lymphoma ● High-dose chemotherapy ● Hematopoietic stem cell transplantationp
r
vNTRODUCTION
Anthracycline-based induction chemotherapy in
atients with diffuse aggressive non-Hodgkin lym- e
16homa (NHL) produces a complete remission (CR)
ate of 50% to 70% and long-term disease-free sur-
ival in approximately 40% of patients [1-3]. How-
ver, 40% to 60% of patients who obtain a CR with
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Autologous Transplantation in NHL
Btandard induction therapy relapse and require con-
entional salvage chemotherapy and/or high-dose
hemotherapy and autologous hematopoietic stem cell
ransplantation (HSCT) [4-6]. The largest random-
zed trial in this setting is the PARMA trial, which
ompared autologous bone marrow transplantation
BMT) and conventional involved-ﬁeld irradiation
ith salvage chemotherapy in chemotherapy-sensitive
HL patients younger than 60 years without any
one marrow or central nervous system involvement
7]. With a median follow-up of 63 months, the BMT
roup had a 5-year event-free survival of 46%, com-
ared with 12% for salvage chemotherapy (P  .001),
nd the overall survival was 53% in the BMT group,
ompared with 32% in the chemotherapy group (P 
038).
Prognostic factors for outcome of high-dose che-
otherapy and HSCT for relapsed aggressive NHL
ave been evaluated in several single-center or multi-
enter trials. Variables correlated with worse overall
r progression-free survival (PFS) were transplanta-
ion while not in remission [8]; bone marrow involve-
ent at relapse, poor performance status at relapse,
nd short duration of ﬁrst CR [9]; and International
rognostic Index status at relapse [10].
We evaluated 429 patients with diffuse aggressive
HL who achieved a CR with induction chemother-
py, relapsed, and received an autotransplant in ﬁrst
elapse (Rel 1) or CR 2 as reported to the Autologous
lood and Marrow Transplant Registry (ABMTR).
he purpose of this analysis was to determine the
rogression-free and overall survival and identify pa-
ient-, disease-, and treatment-related variables asso-
iated with outcome.
ATIENTS AND METHODS
ata Source
The ABMTR is a voluntary organization of more
han 250 transplant centers in the United States, Can-
da, and Central and South America that report data
n consecutive autologous transplants to the statistical
enter of the ABMTR at the Medical College of
isconsin. Data were collected prospectively starting
n 1992. Retrospective data were collected for patients
ho received autologous transplants between 1989
nd 1992. Participating centers register basic informa-
ion on consecutive autologous transplants for all dis-
ase indications. Comprehensive clinical data are col-
ected for a sample of these patients. On the basis of
ata collected in the Centers for Disease Control
ospital Surveys [11], approximately one half of au-
ologous transplants in North America were regis-
ered with the ABMTR during the study period. Phy-
ician review of submitted data, computerized error
hecks, and on-site audits were performed to ensure t
B&MTata accuracy. Patients are followed up longitudinally,
nd information on disease progression and death
rom any cause is updated on a yearly basis.
atients
Between January 1, 1989, and December 30, 1996,
126 patients with diffuse aggressive lymphoma (dif-
use mixed small- and large-cell, diffuse large-cell, or
iffuse large-cell immunoblastic lymphoma according
o the working formulation [12]) who received autol-
gous stem cell transplants in CR 2 or Rel 1 were
egistered with the ABMTR. Four hundred twenty-
ine patients with complete research data reported to
he registry were evaluated for this analysis. Of the
ubset of 429 research patients, 280 were in Rel 1 and
49 patients were in CR 2 at the time of transplanta-
ion. Patients who achieved a partial remission (PR)
efore transplantation, were resistant to chemother-
py, or were untreated were included in the Rel 1
roup. The demographic characteristics of the subset
f 429 research patients were similar to those regis-
ered in terms of age and sex; however, there were
lightly more patients with large-cell immunoblastic
ymphoma among the research patients (P .04). The
-year overall survival was similar in those patients
egistered (46%; 95% conﬁdence interval [CI], 42%-
0%) and the subset of research patients evaluated in
his study (44%; 95% CI, 33%-55%; P  .19).
tatistical Methods
Probabilities of progression, PFS, and overall sur-
ival were calculated by using the Kaplan-Meier prod-
ct-limit estimate [13]. A CR was deﬁned as complete
isappearance of all abnormalities on physical exami-
ation, all imaging abnormalities, and all histologic
vidence of lymphoma after transplantation. A CR
ith residual (persistent) imaging abnormalities of un-
ertain (unknown) signiﬁcance was deﬁned as evi-
ence of minimal imaging abnormalities present after
reatment that were not believed to represent active
isease. A PR was deﬁned as a 50% reduction in all
hysical examination or imaging abnormalities that
asted for 4 weeks. No response to treatment was
eﬁned as a 50% reduction in all physical examina-
ion and/or imaging abnormalities. Progression was
eﬁned as any increase in the size of sites of disease,
evelopment of new sites of disease, or recurrence of
isease after treatment. Overall survival was deﬁned as
he time from transplantation to death from any cause.
FS was deﬁned as time from transplantation to re-
apse, progressive disease, or death from any cause.
or calculations of survival and PFS, patients were
ensored at the time of last follow-up. Chemotherapy
ensitivity was deﬁned as a reduction in measurable
isease with salvage chemotherapy before transplan-
ation that would meet PR criteria as deﬁned previ-
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1usly. Chemotherapy-resistant disease was deﬁned as
reduction in measurable disease with salvage chemo-
herapy that was less than that qualifying for a PR.
hose patients who had a reported chemotherapy
ensitivity status of unknown or those whose data were
issing for chemotherapy sensitivity did not have ad-
quate data available in the ABMTR report to make
his designation and were not included in this analysis.
Cox proportional hazards regression was used to
xamine the association between survival and PFS
ith patient-, disease-, and treatment-related variables
14]. In the multivariate analysis, the following vari-
bles were evaluated: age at transplantation (40 ver-
us 40 years), sex, Karnofsky status at transplanta-
ion (10%-80% versus 90%), histology (diffuse
arge-cell versus diffuse mixed versus immunoblastic
ymphoma), stage at diagnosis and preconditioning
I/II versus III versus IV), bone marrow involvement
t diagnosis, “B” symptoms at diagnosis, lactic dehy-
rogenase (LDH) at diagnosis (normal versus in-
reased), initial chemotherapy regimen (cyclophos-
hamide, doxorubicin, vincristine, and prednisone
ersus other third-generation anthracycline-contain-
ng regimens), number of regimens to achieve ﬁrst CR
1 versus 1), chemosensitivity (resistant versus sen-
itive versus untreated), interval from diagnosis to
ransplantation (12 versus 12 months), bone mar-
ow involvement at the time of transplantation, num-
er of disease sites at transplantation (1 versus 1),
isease sites (nodal only versus extranodal only versus
oth), number of salvage chemotherapy cycles (2
ycles versus 2 cycles), conditioning regimen (total
ody irradiation versus non–total body irradiation
ased), graft type (blood versus marrow), graft manip-
lation, hematopoietic growth factor given after trans-
lantation to promote engraftment (granulocyte col-
ny-stimulating factor [G-CSF] or granulocyte-
acrophage colony-stimulating factor [GM-CSF]
nitiated within the ﬁrst 7 days after transplantation
ersus none [or initiated beyond 7 days]), interval
rom relapse to transplantation (3 versus 3
onths), involved-ﬁeld radiation therapy before or
fter transplantation (yes versus no), and year of trans-
lantation (after 1993 versus before 1993).
Forward stepwise model building was used.
ithin each model, 1 additional signiﬁcant covariate
actor was added at each step, and the remaining
ovariates were re-examined. When there were no
urther covariate factors signiﬁcant at P  .05, model
uilding was stopped. First-order interactions of sig-
iﬁcant covariates were tested. The assumption of
roportional hazards over time was tested for all ex-
lanatory covariates by using a time-dependent co-
ariate in the Cox model. When this indicated differ-
ntial effects over time (nonproportional hazards),
odels were constructed that broke the posttrans-
lantation time course into 2 periods; the maximized (
18artial likelihood method was used to ﬁnd the most
ppropriate breakpoint.
ESULTS
haracteristics
Patient and disease characteristics by response to
retransplantation chemotherapy are detailed in Ta-
le 1. At the time of transplantation, the patients
anged in age from 5 to 71 years, with a median age of
9 years. Most of the cases were categorized as diffuse
arge-cell lymphoma (60%), with diffuse, mixed,
mall-cell, and large-cell lymphoma representing 20%
nd immunoblastic lymphoma representing 20% of
he cases. At the time of initial diagnosis, 62% of the
atients had stage III or IV disease, 35% had B symp-
oms, and 31% of evaluable cases had increased LDH.
ll patients received an anthracycline-containing che-
otherapy regimen initially. Three hundred seventy-
ine (88%) of the 429 patients received a conventional
alvage chemotherapy regimen before proceeding to
igh-dose chemotherapy and autologous stem cell
ransplantation. One hundred forty-nine (35%)
chieved a CR and 179 (42%) achieved a PR with
alvage chemotherapy before transplantation and
herefore had chemotherapy-sensitive disease. Fifty-
ne (12%) were classiﬁed as resistant to salvage che-
otherapy, and 50 (11%) underwent transplantation
ith an untreated relapse.
Two hundred thirty-one patients (56%) relapsed
12 months from diagnosis. Total body irradiation
as used for conditioning in 137 (32%) of the 429
atients; the others received various chemotherapy-
nly regimens. Two hundred nine patients (49%) re-
eived an autologous bone marrow graft, whereas
1% received an autologous peripheral blood stem
ell (PBSC) graft. The remainder of the patients re-
eived a bone marrow plus PBSC graft. Among the
13 patients who received PBSCs (with or without
one marrow), most were selected for PBSC grafts as
matter of protocol for all patients at a transplant
enter (67%). Thirty-nine patients (18%) received a
BSC graft because of actual or suspected bone mar-
ow involvement with lymphoma. The remainder
ere for prior radiation to the pelvis (2.5%), inade-
uate cellularity of bone marrow (2.5%), no bone
arrow performed (5%), and other reasons (physician
reference [n  2], to enhance recovery [n  4], and
atient obesity [n 1]; 4%). Within the PBSC group,
utcomes (survival and PFS) were not signiﬁcantly
ifferent on the basis of the reason for selection of a
BSC graft (protocol versus bone marrow involve-
ent).
Two hundred ﬁfty-three patients (59%) received
-CSF (155 patients), GM-CSF (75 patients), or both
23 patients) within 7 days after transplantation to
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Bable 1. Patient, Disease, and Transplant Characteristics of Patients Receiving Autotransplants for Non-Hodgkin Lymphoma in First Relapse or
econd Complete Remission, 1989 to 1996, by Response to Pretransplantation Chemotherapy
Variable
Sensitive, Achieved
Pretransplantation
CR (n  149)
Sensitive, Achieved
Pretransplantation
PR (n  179)
Resistant to
Chemotherapy
(n  51)
Untreated
(n  50)
P
Value‡
No.
Evaluable
n (%), Median
(Range)
No.
Evaluable
n (%),*
Median
(Range)†
No.
Evaluable
n (%),* Median
(Range)†
No.
Evaluable
n (%),* Median
(Range)†
atient-related variables
Age (y) 149 51 (5-68) 179 48 (11-68) 51 48 (15-71) 50 44 (18-68) .10
Age >40 y (yes/no) 149 114 (77%) 179 129 (72%) 51 35 (69%) 50 31 (62%) .23
Male sex 149 89 (60%) 179 102 (57%) 51 27 (53%) 50 31 (62%) .77
Karnofsky performance status
<90% 138 23 (17%) 172 73 (42%) 47 25 (53%) 48 15 (31%) <.001
isease-related variables at
diagnosis
Stage III/IV disease 149 93 (62%) 179 108 (60%) 51 33 (65%) 48 30 (63%) .94
B symptoms 141 44 (31%) 163 60 (37%) 48 15 (31%) 48 20 (42%) .50
Bone marrow involved 142 15 (11%) 168 30 (18%) 45 8 (18%) 47 5 (11%) .23
LDH levels 149 179 51 50 <.001
Normal 89 (60%) 114 (64%) 22 (43%) 30 (60%)
Increased 35 (23%) 56 (31%) 22 (43%) 19 (38%)
Missing 25 (17%) 9 (5%) 7 (14%) 1 (2%)
Histology 149 179 51 50 .52
Diffuse mixed cell 37 (25%) 35 (20%) 6 (12%) 10 (20%)
Diffuse large cell 80 (54%) 107 (60%) 35 (69%) 31 (62%)
Immunoblastic 32 (21%) 37 (20%) 10 (19%) 9 (18%)
isease-related variables before
transplantation
Initial treatment 148 178 51 50 .90
Chemotherapy only 116 (78%) 142 (80%) 39 (76%) 41 (82%)
Initial Chemotherapy 148 178 51 48 .59
CHOP 62 (42%) 70 (39%) 20 (39%) 18 (38%)
Adriamycin-third generation§ 56 (38%) 80 (45%) 23 (45%) 25 (52%)
Other 30 (20%) 28 (16%) 8 (16%) 5 (10%)
One regimen to achieve first
remission 149 145 (97%) 179 171 (96%) 51 49 (96%) 50 45 (90%) .19
>12 mo from diagnosis to first
relapse before
transplantation 142 90 (63%) 173 101 (58%) 51 20 (39%) 44 20 (45%) .01
>2 cycles of salvage
chemotherapy 143 86 (60%) 166 72 (43%) 47 25 (53%) — .01
>1 site of disease before
transplantation — 175 69 (39%) 49 29 (59%) 50 28 (56%) .01
Disease sites — 169 49 49 .13
Nodal only — 97 (57%) 18 (37%) 26 (53%)
Extranodal only — 28 (17%) 10 (20%) 8 (16%)
Nodal and extranodal — 44 (26%) 21 (43%) 15 (31%)
Bone marrow involved — — 179 15 (8%) 51 6 (12%) 50 0 <.001
Interval from relapse to
transplant (mo) 142 4.84 (1.48-54.9) 173 4.18 (1.48-66.94) 51 4.01 (0.43-18.49) 44 1.83 (0.39-6.68) <.001
>3 mo from relapse to
transplantation (yes/no) 142 118 (83%) 173 126 (73%) 51 36 (71%) 44 6 (14%) <.001
ransplant-related variables
Year of transplant (1994-1996) 149 77 (52%) 179 81 (45%) 51 15 (29%) 50 14 (28%) .004
TBI for conditioning 149 54 (36%) 179 42 (23%) 51 18 (35%) 50 23 (46%) .001
Graft type 149 179 51 50 .005
Bone marrow 63 (42%) 80 (45%) 31 (61%) 35 (70%)
Peripheral blood 68 (46%) 82 (46%) 15 (29%) 9 (18%)
Both 18 (12%) 17 (9%) 5 (10%) 6 (12%)
Use of G-CSF or GM-CSF to
promote engraftment 148 97 (66%) 179 101 (56%) 51 27 (53%) 50 28 (56%) .25
Involved-field radiation after
transplantation 146 50 (34%) 178 68 (38%) 49 15 (31%) 50 22 (44%) .48
Median follow-up of survivors, y
(range) 76 42 (4-122) 64 49 (1-123) 13 33 (15-115) 43 (16-104) .65
HOP indicates cyclophosphamide, doxorubicin, vincristine, and prednisone; TBI, total body irradiation. MACOP, methotrexate, adriamycin, cytoxan, vincristine,
prednisone; MACOP, methotrexate, adriamycin, cytoxan, vincristine, prednisone, bleomycin; PROMACE/CYTABOM, prednisone, methotrexate, cytorabine,
etoposide, cytoxan, bleomycin, vincristine; PROMACE/MOPP, prednisone, cytarabine, cytoxan, etoposide, nitrogen mustard, vincristine, prednisone,
procarbazine; CAP-BOP, cytoxan, adriamycin, prednisone, bleomycin, vincristine, procarbazine; VACOP, etoposide, adriamycin, cytoxan, vincristine,
prednisone; VACOP-B, etoposide, adriamycin, cytoxan, vincristine, prednisone, bleomycin; BACOP, bleomycin, adriamycin, cytoxan, vincristine, prednisone;
COP/BLAM, cytoxan, vincristine, prednisone, bleomycin, adriamycin, methotrexate.
For discrete covariates.
For continuous covariates.
Overall comparison of 4 cohorts by using the Kruskal-Wallis test for continuous variables and the 2 test for categorical variables.
Includes MACOP, MACOP-B, PROMACE/CYTABOM, PROMACE/MOPP, CAP-BOP, VACOP, VACOP-B, M-BACOD, BACOP, and COP/BLAM.
Fisher exact test.119B&MT
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1romote engraftment. Nearly 80% of recipients of
BSC grafts received growth factors to promote en-
raftment, whereas 36% of bone marrow graft recip-
ents received growth factors to promote engraftment.
here was no difference in the use of growth factors
o enhance engraftment for PBSC recipients whether
he indication for PBSC was regarded to be bone
arrow lymphoma involvement or was a matter of
rotocol. The median follow-up for all survivors was
4 months (range, 1-123 months). Transplant-related
haracteristics are given in Table 1.
verall Survival
The probability of 3-year survival was 44% (95%
I, 33%-55%; Figure 1; Table 2). Patients who were
n CR 2 had a probability of 3-year survival of 55%
95% CI, 39%-70%), compared with 40% (95% CI,
3%-59%) for patients who underwent transplanta-
ion with a chemotherapy-sensitive relapse (Rel 1-sen-
itive), 28% (95% CI, 0%-76%) for chemotherapy-
esistant patients (Rel 1-resistant), and 43% (95% CI,
4%-75%) for patients who did not receive salvage
herapy before transplantation (P  .001).
igure 1. Probability of overall and progression-free survival in pati
HL.
able 2. Overall Survival, Progression-Free Survival, and Progression
Variable n
3-y OS
(95% CI) P Value
ll patients 429 44 (33%-55%)
emission status <.001
In CR 149 55 (39%-70%)
No CR 280 38 (24%-54%)
alvage response <.001
CR 149 55 (39%-70%)
PR 179 40 (23%-59%)
Resist 51 28 (0%-76%)
ot treated 50 43 (14%-75%)S, indicates overall survival; PFS, progression-free survival; CI, conﬁden
20rogression-Free Survival
The probability of 3-year PFS was 31% (95% CI,
7%-36%; Figure 1; Table 2). Patients who were in
R 2 at the time of transplantation had a 3-year
robability of PFS of 38% (95% CI, 30%-46%), com-
ared with 25% (95% CI, 19%-32%) for patients who
nderwent transplantation with a chemotherapy-sen-
itive relapse (Rel 1-sensitive), 23% (95% CI, 12%-
5%) for chemotherapy-resistant patients (Rel 1-re-
istant), and 42% (95% CI, 28%-56%) for patients
ho did not receive salvage therapy before transplan-
ation (P  .001).
elapse/Progression
The probability of relapse/progression at 3 years
as 63% (95% CI, 58%-68%; Table 2). The progres-
ion rate for patients who underwent transplantation
n CR 2 was 54% (95% CI, 44%-63%)]. This is
ompared with a progression rate of 72% (95% CI,
4%-78%) for patients who underwent transplanta-
ion with chemotherapy-sensitive relapse (Rel 1-sen-
itive), a 71% progression rate for patients who un-
o underwent transplantation in CR 2 or Rel 1 for diffuse aggressive
fter Autologous Transplantation for Aggressive NHL in CR 2 or Rel 1
3-y PFS
(95% CI) P Value
3-y Progression
(95% CI) P Value
1 (27%-36%) 63 (58%-68%)
<.001 <.001
8 (30%-46%) 54 (44%-63%)
8 (22%-33%) 68 (62%-74%)
<.001 <.001
8 (30%-46%) 54 (44%-63%)
5 (19%-32%) 72 (64%-78%)
3 (12%-35%) 71 (54%-83%)
2 (28%-56%) 51 (35%-66%)ents whRates a
3
3
2
3
2
2
4ce interval; CR, complete remission; PR, partial remission.
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Autologous Transplantation in NHL
Berwent transplantation with a chemotherapy-
esistant relapse (95% CI, 54%-83%), and a 51%
rogression rate for those patients who underwent
ransplantation without receiving salvage chemother-
py (95% CI, 35%-66%; P  .001).
ultivariate Analysis for Overall Survival
Characteristics predictive of an improved overall
urvival after transplantation are shown in Table 3.
atients who achieved CR 2 with salvage therapy
efore transplantation, compared with PR or resistant
isease, had improved survival (P  .001), as did pa-
ients younger than 40 years of age at the time of
ransplantation (P .013). Patients with normal LDH
t diagnosis had better survival within the ﬁrst 6
onths after transplantation (P  .001), and those
hose interval from diagnosis to Rel 1 was longer than
2 months had better survival in the ﬁrst year after
able 3. Multivariate Analysis of Overall Survival after Autotransplan
emission, from 1989 to 1996*
Variable
esponse to salvage chemotherapy before transplantation†
Untreated‡
CR§
PR
Resistant
evel of LDH at diagnosis
Normal
Increased
Within first 6 mo after transplantation
After 6 mo after transplantation
Unknown
nterval from diagnosis to first relapse before transplantation
<12 mo before transplantation
>12 mo transplantation
Within first 12 mo transplantation
After 12 mo after transplantation
ge at transplantation (y)
<40
>40
se of G-CSF or GM-CSF to promote engraftment
No
Yes¶#
Within first 9 mo after transplantation
After 9 months transplantation
Results of testing the effect of centers on overall survival were no
In pairwise comparisons, CR was signiﬁcantly different from PR (
0.27-0.60; P  .001); PR was signiﬁcantly different from resista
“Untreated” was used as baseline group to simplify proportional h
Includes patients with CR and CR with imaging abnormalities of
Time-dependent covariate. In the ﬁrst 12 mo after transplantation,
before transplantation had signiﬁcantly lower mortality rates tha
mortality rates were not signiﬁcantly different.
Time-dependent covariate. In the ﬁrst 9 mo after transplantation
engraftment and those who did not were not signiﬁcantly diffe
growth factors had a signiﬁcantly higher mortality rate than tho
After excluding patients who underwent transplantation in CR; adransplantation (P  .001). Patients who received w
B&MTrowth factors to promote engraftment had an in-
reased risk of mortality for the time period beyond 9
onths after transplantation (relative risk [RR], 2.63;
5% CI, 1.63-4.23) compared with those who did not
eceive growth factors. There was no interaction be-
ween disease sensitivity/response to pretransplanta-
ion chemotherapy and growth factor use or graft
ource in the multivariate models for survival, PFS,
nd progression.
ultivariate Analysis for PFS
Variables predictive of improved PFS were similar
o those for overall survival and are displayed in Table
. Patients who obtained a CR before transplantation
CR 2) had better PFS within the ﬁrst 6 months after
ransplantation than those with PR or resistant disease
P  .001). An interval from diagnosis to Rel 1 longer
han 12 months was associated with improved PFS
for Non-Hodgkin Lymphoma in First Relapse or Second Complete
n
Relative Risk of Death
(95% Confidence Interval) P Value
<.00
44 1.00
141 0.66 (0.41-1.05) .077
173 1.12 (0.73-1.72) .606
51 1.64 (0.99-2.72) .057
.002
242 1.00
126
2.05 (1.40-3.00) <.00
0.85 (0.56-1.30) .465
41 1.52 (0.95-2.43) .084
<.00
179 1.00
230
0.41 (0.30-0.57) <.00
1.23 (0.73-2.06) .441
.013
115 1.00
294 1.46 (1.08-1.97)
<.00
167 1.00
242
0.81 (0.57-1.14) .220
2.63 (1.63-4.23) <.00
cant.
9; 95% CI, 0.43-0.80; P  .001) and resistant (RR, 0.40; 95% CI,
, 0.68; 95% CI, 0.47-0.99; P  .048).
analysis.
wn signiﬁcance.
atients who had a longer interval between diagnosis and ﬁrst relapse
whose interval was short. Beyond 12 mo after transplantation, the
ortality rates for patients who received growth factors to promote
owever, beyond 9 mo after transplantation, patients who received
did not.
for other factors in the model.tation
t signiﬁ
RR, 0.5
nt (RR
azards
unkno
those p
n those
, the m
rent; h
se who
justedithin the ﬁrst 3 months after transplantation (P 
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1001; Figure 2). Patients younger than 40 years at the
ime of transplantation had better PFS (P  .02;
igure 3), as did patients who did not receive G-CSF
r GM-CSF after transplantation to promote engraft-
ent (P  .001; Figure 4). However, an interaction
xists between graft type and growth factors and their
ffect on PFS. Patients who received bone marrow
rafts and growth factors to promote engraftment had
n increased risk of progression or death (RR, 1.87;
5% CI, 1.32-2.64) compared with patients receiving
one marrow without growth factors. Growth factor
se to promote engraftment in recipients of PBSC
roducts was not associated with an increased risk of
reatment failure compared with bone marrow recip-
ents who did not receive growth factors.
ultivariate Analysis for Posttransplantation
rogression or Relapse
Patients who did not obtain CR 2 before trans-
lantation had an increased risk of relapse or progres-
able 4. Multivariate Analysis of Posttransplantation Progression-Free
elapse or Second Remission, from 1989 to 1996
Variable
esponse to salvage chemotherapy before transplantation†
Untreated
CR‡
Within first 6 mo after transplantation
After 6 mo posttransplantation
PR
Resistant
nterval from diagnosis to first relapse
<12 mo before transplantation
>12 months before transplantation
Within first 3 mo after transplantation
After 3 mo posttransplantation
atient’s age at transplantation (y)
<40
>40
raft type and use of G-CSF or GM-CSF to promote engraftmen
BM, no growth factor (G or GM)
BM, with growth factor (G or GM)
PB (BM), no growth factor (G or GM)
PB (BM), with growth factor (G or GM)
The results of testing the effect of centers on progression-free sur
In pairwise comparisons, CR was signiﬁcantly different from PR in
different beyond 6 mo (P  .94). CR was also signiﬁcantly differ
signiﬁcantly different beyond 6 mo (P  .60).
Time-dependent covariate. In the ﬁrst 6 mo after transplantation
progression-free survival compared with those who were untrea
higher treatment-failure risk than those who were untreated.
Time-dependent covariate. In the ﬁrst 3 mo after transplantation, t
before transplantation had a signiﬁcantly lower treatment-failur
transplantation, the treatment-failure risks were not signiﬁcantl
The results of testing the interaction effect of graft type and use of
signiﬁcant. There was no signiﬁcant difference between patient
receiving PB only, with or without growth factor. G indicates gion within the ﬁrst 6 months after transplantation e
22P  .005). A short interval (12 months) from diag-
osis to transplantation was associated with a signiﬁ-
antly increased risk of relapse in the ﬁrst 3 months
fter transplantation (P  .001), as was the use of
-CSF or GM-CSF after transplantation to promote
ngraftment (P  .001). As with the multivariate anal-
sis of the PFS, there was an interaction between the
ffect of graft type and growth factors on the risk of
elapse/progression. Recipients of bone marrow grafts
nd growth factors to promote engraftment had an
ncreased risk of progression compared with patients
ho received bone marrow grafts without growth fac-
ors (RR, 2.46; 95% CI, 1.68-3.60). This effect was
he same for patients receiving G-CSF or GM-CSF
fter transplantation. Compared with patients who
eceived bone marrow without growth factors, pa-
ients who received PBSCs did not seem to be at
ncreased risk of progression, whether or not they
eceived growth factors to promote engraftment (Ta-
le 5). Figure 5 demonstrates the probability of dis-
al after Autotransplantation for Non-Hodgkin Lymphoma in First
n
Relative Risk of Progressive
or Recurrent Lymphoma
(95% Confidence Interval) P Value
<.00
40 1.00
136
0.60 (0.35-1.04) .07
1.70 (1.00-2.89) .05
166 1.72 (1.11-2.67) .01
49 1.93 (1.17-3.18) .02
<.00
172 1.00
219
0.35 (0.23-0.52) <.00
0.94 (0.68-1.32) .74
112 1.00
279 1.40 (1.06-1.86) .02
<.00
118 1.00
64 1.87 (1.32-2.64) <.00
43 0.90 (0.58-1.39) .63
166 1.07 (0.80-1.42) .67
ere not signiﬁcant.
t 6 mo after transplantation (P  .001). They were not signiﬁcantly
resistant in the ﬁrst 6 mo after transplantation (P  .001) and not
nts who underwent transplantation in CR 2 had no difference in
er 6 mo beyond transplantation, those with CR 2 had a marginally
tients who had a longer interval between diagnosis and ﬁrst relapse
han those whose interval was short (12 mo). Beyond 3 mo after
ent.
factors to promote engraftment on progression-free survival were
ing both peripheral blood (PB) and bone marrow (BM) and those
cyte; GM, granulocyte-macrophage.Surviv
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Beceive myeloid growth factors after transplantation to
nhance engraftment.
ISCUSSION
High-dose chemotherapy and autologous HSCT
as become the standard of care for patients with
ecurrent aggressive NHL with chemotherapy-sensi-
ive disease, on the basis of the results of the PARMA
tudy [7]. Several small trials evaluated prognostic
actors for patients with relapsed aggressive NHL who
eceive high-dose chemotherapy and autologous
ransplantation [8-10,15,16]. Many identify remission
tatus at the time of transplantation as having prog-
ostic signiﬁcance [8,9,15]. For example, in a study by
rince et al. [8], patients who received transplants in
R 2 had a signiﬁcantly better 4-year PFS of 61%
ompared with 25% for those patients who underwent
ransplantation in PR (P  .0001). Other characteris-
Figure 2. Probability of progression-free survivalFigure 3. Probability of progression-free surviv
B&MTics identiﬁed as predictive for an improved outcome
ith transplantation have included a lack of bone
arrow involvement at relapse [9], good performance
tatus at relapse [9,10], long duration of ﬁrst CR [9],
ormal LDH at transplantation [15], few prior che-
otherapy regimens administered [15], and low In-
ernational Prognostic Index at relapse [16]. In the
nalysis by Guglielmi et al. [9], the effects of 3 adverse
rognostic factors (bone marrow involvement at re-
apse, low performance status at relapse, and short
uration of ﬁrst CR) were cumulative: patients with
o adverse factors had an event-free survival of 69%,
hose with 1 adverse factor had an event-free survival
f 48%, and those with 2 or 3 adverse factors had an
vent-free survival of 21%. Our analysis was under-
aken to evaluate the patient, disease, and transplant
haracteristics that could assist in predicting the out-
ome of patients.
Our ﬁndings, in a large number of patients with
from diagnosis to relapse before transplantation.al by age at the time of transplantation.
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1igure 4. Probability of progression-free survival in patients who received or did not receive myeloid growth factors after transplantation for
nhanced myeloid recovery and graft type.able 5. Multivariate Analysis of Posttransplantation Progression/Relapse after Autotransplantation for Non-Hodgkin Lymphoma in First Relapse or
econd Remission, from 1989 to 1996
Variable n
Relative Risk of Progressive
or Recurrent Lymphoma
(95% Confidence Interval) P Value
esponse to salvage chemotherapy before transplantation† <.00
Untreated 40 1.00
CR‡ 136
Within first 6 mo after transplantation 0.51 (0.27-0.94) .032
After 6 mo posttransplantation 1.75 (0.99-3.10) .05
PR 166 1.87 (1.16-3.01) .01
Resistant 49 1.79 (1.03-3.13) .04
nterval from diagnosis to first relapse <.00
<12 mo before transplantation 172 1.00
>12 mo before transplantation§ 219
Within first 3 mo after transplantation 0.32 (0.19-0.51) <.00
After 3 mo posttransplantation 0.90 (0.64-1.28) .57
raft type and use of G-CSF or GM-CSF to promote engraftment <.00
BM, no growth factor (G or GM) 118 1.00
BM, with growth factor (G or GM) 64 2.46 (1.68-3.60) <.00
PB (BM), no growth factor (G or GM) 43 1.15 (0.72-1.83) .55
PB (BM), with growth factor (G or GM) 166 1.25 (0.90-1.74) .17
The results of testing the effect of centers on progression-free survival were not signiﬁcant.
In pairwise comparisons, CR was signiﬁcantly different from PR in the ﬁrst 6 mo after transplantation (RR, 0.46; 95% CI, 0.27-0.80;
P  .005). They were not signiﬁcantly different beyond 6 mo (P  .67). CR was also signiﬁcantly different from resistant in the ﬁrst 6 mo
after transplantation (RR, 0.29; 95% CI, 0.15-0.52; P  .001) and not signiﬁcantly different beyond 6 mo (P  .92).
Time-dependent covariate. In the ﬁrst 6 mo after transplantation, patients who underwent transplantation in CR 2 had signiﬁcantly lower
progression rates than those who were untreated; after 6 mo beyond transplantation, the rates of progression were marginally signiﬁcantly
higher than those of patients who were untreated.
Time-dependent covariate. In the ﬁrst 3 mo after transplantation, those patients who had a longer interval between diagnosis and ﬁrst relapse
before transplantation had signiﬁcantly lower progression rates than those whose interval was short (12 mo). Beyond 3 mo after
transplantation, the progression rates were not signiﬁcantly different.
Results of testing the interaction effect of graft type and use of growth factors to promote engraftment on progression were signiﬁcant
(P  .015). In pairwise comparisons, patients who received both bone marrow (BM) and growth factor had a signiﬁcantly higher
progression rate than those who received peripheral blood (PB) with or without growth factor. Compared with the patients who received
both PB and growth factor, the relative risk was 2.04 (95%CI, 1.41-2.92; P  .001); for the patients who received PB without growth factor,
the relative risk was 2.06 (95% CI, 1.27-3.42; P  .004). There was no signiﬁcant difference between patients who received both PB and
BM and those who received PB only, with or without growth factor.
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Bggressive NHL who received autologous transplants
n CR 2 or Rel 1, are consistent with those of many of
he previous reports. Remission status at the time of
ransplantation, interval from diagnosis to transplan-
ation, age at transplantation, and LDH at the time of
iagnosis are characteristics frequently identiﬁed as
rognostic factors. However, the ﬁnding of adverse
ffects with the use of myeloid hematopoietic growth
actors after transplantation to enhance engraftment is
ew. Although this information raises concerns about
he use of myeloid growth factors after transplanta-
ion, it is a ﬁnding that should be veriﬁed in other
tudies. An adverse effect of growth factors was not
dentiﬁed for recipients of PBSC grafts, the predom-
nant source of stem cells for autologous transplanta-
ion for the last few years. Because more NHL con-
amination can be found in bone marrow as opposed
o blood [17], this may account for the increased
ncidence in that subset.
The biologic basis for an adverse effect of post-
ransplantation myeloid growth factors is unclear. Al-
hough receptors for G-CSF and GM-CSF are de-
ectable on myeloid cells, they have not been detected
n lymphoma cells [18]. Randomized trials in which
-CSF or GM-CSF has been evaluated for the pre-
ention of neutropenic fever or infection in NHL
atients receiving standard chemotherapy [19,20] or
ransplants [21-23] have not identiﬁed an adverse ef-
ect. However, these studies were powered to detect
ifferences in rates of infection and fever and not of
ymphoma progression. There have been some re-
orts of myeloid growth factors stimulating the clonal
rowth of nonhematopoietic tumor cells despite the
bsence of receptors [24].
It has been demonstrated in animal models [25]
nd also in humans [26] that the administration of
igure 5. Probability of relapse in patients who received or did not
ecovery and graft type.-CSF polarizes toward T-helper 2 (Th 2) cells that i
B&MTroduce the cytokines interleukin-4 and interleukin-
0. When G-CSF is used for the mobilization of
ealthy donors for allogeneic transplantation, this al-
ered Th 1/Th 2 ratio may be beneﬁcial in reducing
he incidence of graft-versus-host disease [27]. How-
ver, in autologous transplantation patients, the sig-
iﬁcance of this altered ratio is not known. One hy-
othesis could be that this alteration of the Th 1/Th 2
atio in autologous transplantation patients might in-
ibit the patient’s immune system from responding
dequately to tumor antigens. GM-CSF does not
eem to alter the Th 1/Th 2 ratio in this manner [28].
ecause patients in this study had a worse outcome if
hey received autologous bone marrow with either
-CSF or GM-CSF after transplantation, this expla-
ation may not necessarily be substantiated.
The adverse effect of growth factors in this group
f patients may also be explained by patient selection
actors that were not accounted for in this analysis.
owever, although growth factors were used prefer-
ntially in recipients of PBSC grafts, there was no
nteraction between growth factor use and disease
ensitivity/response in the multivariate models to sug-
est that patients with adverse sensitivity were selec-
ively given growth factors. As well, there was no
pparent difference in the distribution of growth fac-
or use based on the number of prior chemotherapeu-
ic regimens (data not shown). Therefore, although
his study cannot entirely eliminate the possibility of
election bias in the use of growth factors to enhance
ngraftment, a few common clinical variables do not
eem to indicate the presence of a selection bias.
Patients who are candidates for transplantation
hould be considered for HSCT at the time of relapse
ith aggressive NHL, on the basis of the results of the
ARMA trial [7]. Information from our study has
myeloid growth factor after transplantation for enhanced myeloidreceivedentiﬁed several prognostic characteristics, such as
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1ge, LDH, length of initial CR, and response to sal-
age chemotherapy, that may assist the physician and
atient in evaluating the likelihood of long-term dis-
ase-free survival after an autologous transplantation.
Even in the best of situations, only 40% to 50% of
atients with chemotherapy-sensitive relapsed aggres-
ive NHL have long-term disease-free survival with
tandard autologous stem cell transplantation, as out-
ined in this study. Therefore, the modiﬁcation of
ransplantation regimens by the addition of alternative
ovel agents is being evaluated. Monoclonal antibod-
es such as rituximab [29], radioimmunoconjugates
uch as iodine 131 tositumomab [30,31] or yttrium 90
britumomab [32], and idiotype vaccines [33] are po-
entially additive or synergistic agents being evaluated
n clinical trials in an attempt to improve outcomes in
hese patients.
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